Major Novartis Shareholder Calls for Board Shake-Up After Two Failed Drug Trials
Artisan Partners wants Novartis board changes after Avidity’s del-desiran and pelacarsen failed late-stage trials and wiped out $30B in value.
/ 83 items
#XY News-Driven Stocks↓
Novartis Muscle-Disease Drug Misses Phase 3 Goal, Shares Drop After $12 Billion Avidity Bet
Novartis del-desiran missed its Phase 3 HARBOR goal in DM1. Shares fell ~9–10% a day after a cholesterol-drug miss. Sarepta and Dyne also dropped.
Another Setback for Novo: Two More Ziltivekimab Cardiovascular Trials Ended
Novo Nordisk stopped the HERMES and ATHENA trials of ziltivekimab after a data committee said they were unlikely to succeed, following the ZEUS miss.
Amgen Slides After BMO Downgrade and Rival Heart-Drug Miss
BMO cut Amgen to Market Perform on valuation after a 34% YTD rally. A Novartis Lp(a) trial miss also raises questions for Amgen’s olpasiran.
Novartis Pauses Cell Therapy Trials After Three Deaths as MS Pill Succeeds in Late-Stage Studies
Three deaths halt Novartis rap-cel trials in autoimmune disease. Positive Phase 3 data for remibrutinib in relapsing MS announced the same day.
Ionis-AstraZeneca Heart Trial Fails; Analysts See Neutral-to-Negative Read-Through for Alnylam
Eplontersen failed to reduce heart events in 1,432 ATTR-CM patients. Results raise questions on silencer-plus-stabilizer use and for Alnylam’s pipeline.